RevitalVision is a SaaS-based, digital health startup headquartered in Israel. We offer a unique solution to millions with poor or insufficient vision whose needs are unmet by existing vision treatments. Our non-invasive technology enhances eyesight neurologically. We utilize brain science and a proprietary algorithm to effectively stimulate the brain’s visual cortex to improve vision. Our technology has been clinically validated to enhance vision outcomes with long-lasting results in a wide range of eye diseases and vision impairments, with a significant impact on vision and quality of life. Our product – a home-based vision-training software program operates directly from a standard web browser on any personal computer, without the need for any special hardware. Our customers include: 1) Eyecare professionals (B2B) who prescribe the home-based treatment with our software for specific conditions such as amblyopia (lazy eye) and low vision, and 2) Consumers (B2C) seeking wellness and post-surgery solutions, beyond available treatments.
Our technology is the only FDA-cleared product with an efficacy claim to improve vision in amblyopia (Lazy eye) in patients age 9 or older and is CE Marked with a broad intent for use – to improve vision above age 9.
In the past year, 3 new RCTs have demonstrated the efficacy of RevitalVision in improving vision in keratoconus patients.
All three studies demonstrated statistically significant clinical outcomes with an average improvement of 1.7-2.8 LogMar lines in distance BCVA. Many participants experienced notable improvement in their subjective vision and life quality.
- An RCT recently published in AJO demonstrated an average improvement of 1.7 LogMar lines in best spectacle-corrected vision in non-progressing keratoconus patients who are intolerant to CL.
- An RCT presented at the recent ASCRS meeting in Boston demonstrated a 2.5 LogMar lines improvement in BCVA and a 100% improvement in contrast sensitivity in stable keratoconus patients post-crosslinking.
- A new RCT from Shamir Medical Center on non-progressing keratoconus patients with poor BCVA (20/40-20/100) was accepted for live presentation at the upcoming ASCRS meeting in Los Angeles. The average improvement in BCVA was 2.8 LogMar lines for distance and 3 LogMar lines for near, and the average improvement in contrast sensitivity was 100%.
This new accumulated evidence should encourage corneal specialists to offer this advanced, non-invasive, and non-risk therapy to keratoconus patients, who have already maximized their treatment options but are still unhappy with their vision.